| abstract |
The present application discloses compounds that have efficacy in modulating NMDA receptor activity. Such compounds can be used to treat conditions such as depression and related disorders. Other pharmaceutically acceptable dosage forms of the compounds are also disclosed, including oral dosage formulations and intravenous formulations. |